BioMed Leaders KRBP, NMLSF, VERU, AIMLF Latest Report

NEW YORK, June 07, 2022 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from the CEOs of: Kiromic BioPharma (NASDAQ:KRBP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: VERU) and AI/ML Innovations (OTC: AIMLF) (CSE: AIML). As the global pharmaceutical market surpasses $1.3 trillion (Statista), emerging technologies and healthcare research innovations are unlocking new opportunities for exponential growth. As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for alpha-generating upside potential. The Wall Street Reporter highlights the latest comments from industry thought leaders who are shaping our world today and in the decades to come:

Pietro Bersani, CEO of Kiromic BioPharma (NASDAQ: KRBP): “The Gamma Delta T Cell Pipeline Grows to Five”
Kiromic BioPharma (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data-mining platform to discover and develop cell and gene therapies focused on immuno-oncology, is engaged in a sponsored research agreement with principal investigator James W. Welsh, MD of the University of Texas MD Anderson Cancer Center.
As part of the two-year SRA, preclinical in vivo data will be generated from Kiromic’s Gamma Delta T cell allogeneic therapies. This SRA is intended to evaluate the efficacy and patient safety outcomes to support three investigational new drug applications (INDs) to the United States Food and Drug Administration. KRBP CEO Pietro Bersani said, “We believe SRA will enable us to efficiently and rapidly generate key in vivo data that will demonstrate the synergistic benefits of our Gamma Delta T cell therapies in combination with existing cancer treatment modalities. . total number of our product candidate therapies to five. We expect to begin activation of the Delta T cell clinical trial by the end of this year. We believe that using non-genetically engineered Gamma Delta T cells as our first-in-human study is ideal for establishing the tolerability and safety of our proprietary allogeneic cell therapy platform. »
News from Kiromic BioPharma (NASDAQ: KRBP):

AI/ML Innovations (OTC: AIMLF) (CSE: AIML) Chairman, Tim Daniels: “AI/ML holds key patents for a multi-billion dollar market in wearable healthcare devices”
AI/ML Innovations (OTC: AIMLF), a featured presenter on Wall Street Reporter’s “Next Super Stock” investor conference series, recently updated investors on digital health portfolio growth initiatives from AIMLF, including HealthGauge, a wearable personal health monitoring and management system, using artificial intelligence and machine learning, and Tech2Heal, a European innovator in mental health apps.

AIMLF’s landmark patent stance for wearable health monitors is particularly attractive to investors – which could allow AIMLF to collect licensing fees and royalties on the $13.8 billion worth of devices. smart wearables (expected to reach $37.4 billion by 2028. Source: Verified Market Research). AIMLF is now beginning to license its technologies to healthcare apparel companies and collect royalties. With typical royalties of 2% of gross sales, the AIMLF could potentially generate significant recurring revenue from companies infringing on its broad patent position in the nearly $14 billion healthcare apparel market.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:

AIMLF’s Health Gauge subsidiary recently obtained a patent from the United States Patent and Trademark Office (US Patent No. 11183303), entitled “Wearable Health Monitors and Methods of Monitoring Health”. The patent covers cardiovascular monitoring, predictive health analytics, behavioral analytics, and 64 other claims, including the use of multiple wearable health monitor configurations, in conjunction with biological signal analysis methods and health metrics monitoring (via Health Gauge AI-based software) to help the user achieve their personal health and wellness goals.

AIMLF reports ramping growth in its portfolio company Tech2Heal, a European innovator in mental health apps. Tech2Heal is positioned for explosive revenue growth as European healthcare mandates now provide around €2,500 per patient per year for mental well-being. Tech2Heal has just signed with a French multinational manufacturer, to provide mental wellness support to its 170,000 employees worldwide, and further corporate contracts are in the works. Tim Daniels also updated investors on AIML’s growing pipeline of health technology M&A opportunities, which could have a positive impact on maximizing shareholder value in the months ahead.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:

Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, MD: “Nova Psilocybin-based therapeutic showing great promise for autism and Othe Neuro-inflammatory disorders »
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), a guest presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference, advances new psilocybin therapies, targeting autism spectrum disorders, a need unmet medical device with multi-billion dollar market potential. NMLSF’s Chief Medical Officer, Dr. Marvin Hausman, MD, has decades of success promoting new drugs through FDA regulatory pathways, through to commercialization, generating billions of dollars in revenue. Dr. Hausman is now bringing the “same playbook” to NMLSF for his psilocybin therapies targeting Fragile X, and then potential expansion to treat other neuroinflammatory disorders, including Alzheimer’s and Parkinson’s. The NMLSF plans to submit a clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for fragile X syndrome in the coming weeks.

NMLSF is a world leader in first-class psilocybin therapies and complementary diagnostics for neuroinflammatory disorders. NMLSF is the first biotechnology company to obtain “Orphan Drug Designation” from the FDA in the United States and European Union for the use of psilocybin in the treatment of FXS. In his interview with The Wall Street Reporter, Dr. Hausman explains his strategy for advancing NMLSF’s drug pipeline through commercialization, as he has successfully done with other new drugs over his decades-long career. .
Watch the NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) video:

“The recently completed preclinical study of repeating low doses of our psilocybin drug – every other day for 2 weeks, showed clinical responses that far exceeded our expectations. We significantly modulated behavioral and cognitive defects , such as recognition memory, in the FXS.” The NMLSF plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS. “Autism Spectrum Disorders (“ASD”) and in particular FXS, the largest genetic cause of ASD, continue to have unmet medical needs. NOVA scientists over the past two years have cast the groundwork for the development of a potential new psilocybin-based microdose treatment for ASD,” said NMLSF Chief Medical Officer Dr. Marvin S. Hausman, MD.
Watch the NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) video:

Veru Inc. (NASDAQ: VERU) CEO Mitchell Steiner, MD: “Sabizabulin takes important step in fight against COVID-19”
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, today announced positive efficacy and safety results from a planned interim analysis of the Phase 3 COVID-19 clinical trial, randomized, double-blind, placebo-controlled trial evaluating oral sabizabulin 9 mg versus placebo in 150 hospitalized COVID-19 patients at high risk of acute respiratory distress syndrome (ARDS). The Independent Data Safety Monitoring Board unanimously recommended that the Phase 3 study be terminated early due to its efficacy, and further noted that there were no safety issues. been identified.
CEO Mitchell Steiner, MD said, “This study represents an important milestone in the global fight against COVID-19, as sabizabulin is the first drug to demonstrate a clinically and statistically significant reduction in deaths in hospitalized patients with COVID-19. Moderate to severe COVID-19. We are confident that sabizabulin, with its dual antiviral and anti-inflammatory properties that demonstrated positive efficacy and safety results in the Phase 3 COVID-19 study, may be the oral therapy that has greatly need hospitalized patients with moderate to severe COVID-19. ”
News from Veru Inc. (NASDAQ: VERU):


Wall Street Reporter (est. 1843) is the leading provider of financial information, focused on giving investors direct access to CEOs of promising publicly traded companies and market experts. Nothing in this news summary should be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer and relevant SEC 17B disclosures here:

About Wall Street Reporter’s Next Super Stock conference:

NEXT SUPER STOCK live from The Wall Street Reporter! The conference is dedicated to showcasing select companies that have put in place near-term catalysts that can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next live stream event:



(212) 871-2057 ext 7

About Larry Noble

Check Also

Stock to buy: This multibagger IT stock is top pick for November, brokerage sees 20% returns, buy

Outlook and stock returns INFO is one of the leading large cap IT companies in …